New Drug Causes 20 Percent Weight Loss in Early Amgen Results
The pharmaceutical manufacturer Amgen announced on Tuesday that an experimental obesity drug helped patients lose up to 20 ...
What's Next for Amgen Obesity Drug After Investors Disappointed by Results
Shares in Amgen fell on Tuesday after they announced the results of a trial for their weight loss drug MariTide.
Amgen Drug Delivers More Weight Loss Than Competitors
A new weight loss drug called MariTide caused 20 percent weight loss in a recent trial, even better than Wegovy or Ozempic.
Amgen says obesity drug caused up to 20% weight loss after a year, with no plateau
The results shed light on how MariTide may measure up to weight loss injections from Novo Nordisk and Eli Lilly and other ...
Amgen's obesity drug causes up to 20% weight loss, trial data weighs on shares
Amgen's experimental drug MariTide led to an average weight loss of up to 20% in a year-long mid-stage trial of people who ...
BioPharma Dive1d
Amgen obesity drug cuts weight in study, but results miss Wall Street’s high mark
Shares in Amgen fell by double digits Tuesday on results for the company’s MariTide shot, which is viewed as a potential ...
pharmaphorum19h
Amgen's big reveal of obesity data falls a bit flat
William Blair's assessment is that MariTide is an improvement on current obesity therapies with a profile that "will be ...
STAT1d
Amgen drug leads to substantial weight loss in study, but questions remain about competitiveness
An Amgen obesity drug helped participants lose a substantial amount of weight, but questions about how competitive it could ...
FierceBiotech1d
Amgen's monthly obesity drug matches competition in phase 2, but investors are unimpressed
MariTide, which like Eli Lilly’s Zepound is a dual agonist of the GLP-1 and GIP receptors, demonstrated an average weight ...
Amgen's weight-loss drug fails to impress in study; shares plunge
Amgen's experimental drug MariTide led to an average weight loss of up to 20% in a year-long mid-stage trial of nearly 600 ...
Amgen’s MariTide: Hold Rating Amid Efficacy and Safety Concerns in Obesity Treatment
Mizuho Securities analyst Salim Syed has maintained their neutral stance on AMGN stock, giving a Hold rating yesterday.Don't Miss our Black ...
AMGN Stock Down Despite Strong Data From Obesity Drug Study
Data from a phase II study shows that AMGN's obesity drug MariTide leads to sustainable weight loss, robust improvements in cardiometabolic parameters and strong HbA1c reduction.